病毒性肝炎免疫治疗的进展以及治疗
摘要
病毒性肝炎是对人类健康危害极大的传染性疾病,中国又是病毒性肝炎的高发区,对该病的治疗显得尤为重要。抗病毒治疗是病毒性肝炎的重要治疗手段之一。目前临床主要使用干扰素和核苷类似物等药物进行治疗,但效果不能令人满意。针对病毒性肝炎的免疫治疗正被人们所重视,调节机体的免疫状态达到治疗的目的,特别是免疫基因治疗为病毒性疾病的治疗开辟了新天地。论文就目前病毒性肝炎免疫治疗的进展以及治疗进行研究。
关键词
全文:
PDF (English)参考
曹雪涛.免疫基因治疗的研究现状与发展趋势[J].中国肿瘤生物治疗杂志,1996 (04): 243-250.
Mancini M. DN A — mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state[ J].Proc Natl Acad Sci LSA, 1996, 93( 22): 12496-12501.
Mancini M, Hadchouel M, Davis HL et al DN A —mediated immunization in a transgenic mouse model of the hepatitis B surfase antigen chronic carrier state [J] . Pioc Natl Acad Sci L SA, 1996 93(22):12496.
MajorME, V itvitski L MinkMA, etal.DNA—based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid [J] . J Virol, 1995 (9):5798.
Monto Ho. Assessment of Response to Therapy of primary Breast Cancer by Mammography and physical Examination [J]. Cancer Res, 1995(81):2093.
Vitiello A, Ishioka G , Grey HM , et al.Development of a lipopeptide- based therapeutic vaccine to treat chronic HBV infection I.Induction of a primary cy totoxic T lym phocyte response in humans[J] .J C lin Invest , 1995 (1):341.
Boh janen PR, Colvin RA, Puttaraju M , et al. A smallcircular TAR RNA decoy specifically inhabits Tat -activated HIV -1 transcription [J] .Nucleic Acids Res, 1996 (19):2733.
Reusser M. Cytotoxic T — lymphocyte Response to Cytomegalo virus After Human Allogeneic Bone M arrow T ransplantation: Pattern of Recovery and Correlat in w it h cyt omegalov: rus 丄nfection and Diseasa[J] . Blood, 1991(78): 1373.
Tokushige K. Expression and Immune Response to Hepatitis C virus coie DN A —Based Vaccine onstliact?[J] . Hepatology, 1996 (01):14- 20.
Cavanaugh VJ, Guidotti LG , C hisari FV, et al.Interleukin -12 inhibits hepatitis B virus replication in transgenic mice [J] .J Virol,1997(4):3236.
李晓敏.细胞因子基因肌肉注射的基因疗法[J].国外医学免疫分册,1995(06):331.
DOI: http://dx.doi.org/10.26549/ptvd.v1i1.5426
Refbacks
- 当前没有refback。
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。